ERG Clinical Research — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2023	Research	$194,980	2
2022	Research	$15,866	3
2021	Research	$65,440	16

Breakdown

Who paid Research payments · program years 2021–2023

Boehringer Ingelheim Pharmaceuticals, Inc. $207,615 3 payments
Purdue Pharma L.P. $53,472 13 payments
Vanda Pharmaceuticals Inc. $11,025 4 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $4,174 1 payment

Studies the money was for Research payments · program years 2021–2023

Connex 1 $153,655 1 payment
Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States $50,242 11 payments
Connex X $41,325 1 payment
BI 425809 Pivotal efficacy study 1 $12,635 1 payment
A Study to Evaluate the Efficacy and Safety of Tasimelteon in Treating Sleep Disturbances in Individuals With Autism Spectrum Disorder $11,025 4 payments
A Phase Iiib Multi-Center, Open-Label, Mirror-Image, Study in Adult Subjects With Schizophrenia Treated Prospectively for 6-Months With Abilify Mycite $4,174 1 payment
Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States $3,230 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.